

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>5</sup> :</b>  <b>C12N 5/08</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 91/09115</b>  <b>(43) International Publication Date:</b> <b>27 June 1991 (27.06.91)</b>
<b>(21) International Application Number:</b> PCT/EP90/02195 <b>(22) International Filing Date:</b> 13 December 1990 (13.12.90) <b>(30) Priority data:</b> 89403491.7                      14 December 1989 (14.12.89) EP <b>(34) Countries for which the regional or international application was filed:</b> AT et al. <b>(71) Applicant (for all designated States except US):</b> SCHERING-PLOUGH [FR/FR]; 92, rue Baudin, F-92307 Levallois-Perret (FR). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> BANCHEREAU, Jacques [FR/FR]; 25, avenue Paul-Santy, F-69130 Ecully (FR). ROUSSET, Françoise [FR/FR]; 126, rue Commandant-Charcot, F-69005 Lyon (FR).		<b>(74) Agent:</b> BEAUCHAMPS, Georges; Cabinet Weinstein, 20, avenue de Friedland, F-75008 Paris (FR). <b>(81) Designated States:</b> AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US. <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHOD OF MAKING FACTOR-DEPENDENT HUMAN B CELL LINES  <b>(57) Abstract</b>  <p>A method is provided for establishing factor-dependent human B cell lines capable of secreting immunoglobulin of a desired specificity and capable of long term culturing. The method includes selecting a resting B cell having immunoglobulin of the desired specificity and culturing it in the presence of an agent capable of cross-linking its CD40 surface antigens. Long term culture requires the continued presence of the cross-linking agent. Preferably, the cross-linking agent is a monoclonal antibody specific for the CD40 antigen, presented by non-replicating mammalian cells expressing Fcγ-R11.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CI	Côte d'Ivoire	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

- 1 -

METHOD OF MAKING FACTOR-DEPENDENT HUMAN B CELL LINESField of the invention

5 The invention relates generally to the field of immunology, and more particularly, to methods of establishing longterm cultures of human lymphoid B cells capable of producing antibodies.

BACKGROUND

10 Readily available hybridomas producing human monoclonal antibodies would give rise to valuable pharmaceutical and diagnostic compositions. Areas where human monoclonal antibodies may prove directly useful include  
15 passive immunization against viral and bacterial diseases, elimination of drugs and toxins, diagnostic imaging of neoplasms, targeting of drugs to tumors, and modulation of autoimmune disorders. Indirect utility of human monoclonal antibody-producing hybridomas lies with their use as a source of messenger RNA for making  
20 genetically engineered monoclonal antibodies in bacteria, or other non-human expression systems, e.g. Skerra et al, Science, Vol. 240, pgs. 1038-1041 (1988); and Moore et al, U.S. patent 4,642,334. Such methods have the great advantage of providing antibodies or  
25 binding compositions free of potentially dangerous human contaminants. Unfortunately, to date the use of human monoclonal antibodies in in vivo trials has been very limited, e.g. Burnett et al, in Strelkauskas, ed. Human Hybridomas: Diagnostic and Therapeutic Applications  
30 (Marcel Dekker, New York, 1987). A major stumbling block to progress in the field has been the inability to obtain long term and/or immortalized human B cell lines, e.g. James et al, J. Immunol. Meth., Vol. 100, pgs. 5-40 (1987); and Van Brunt, Biotechnology, Vol. 7, pgs.  
35 561-563 (1989).

- 2 -

The availability of methods for routinely producing such lines, and methods of enriching and expanding antigen-specific subpopulations of B cells, would be a major breakthrough for the application of human monoclonal antibodies.

#### SUMMARY OF THE INVENTION

The invention is directed to a method of establishing factor-dependent human B cell lines and antigen-specific subpopulations. The method includes the steps of isolating resting B cells or antigen-specific subpopulation carrying immunoglobulin of a desired specificity, and culturing the B cell or antigen-specific subpopulation in the presence of an agent capable of cross-linking its CD40 antigens. Preferably, the cross-linking agent is an immobilized monoclonal antibody specific for CD40. More preferably, the monoclonal antibody is immobilized on a solid phase or non-aqueous phase liquid substrate, such as microspheres, liposomes, or cellular membranes. Most preferably, the anti-CD40 monoclonal antibody is immobilized by culturing the B cell or antigen-specific subpopulation with non-replicating mammalian cells expressing the surface molecule, CDw32, also known as Fc $\gamma$ RII, whenever the CD40-specific monoclonal antibody is of the IgG isotype. In this case, immobilization is achieved by the binding of the Fc portion of the antibody molecules with the Fc $\gamma$  receptor. Longterm culturing of the B cell clone or subpopulation requires the continued presence of a cross-linking agent, and the culture growth rate is enhanced by the presence of the cytokines interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), and interferon- $\gamma$  (INF- $\gamma$ ), either alone or in combination.

The invention also includes a method for producing

- 3 -

Epstein-Barr virus (EBV)-transformed B cell lines wherein transformation takes place in the presence of a CD40 cross linking agent.

- 5 An important feature of the invention is the use of resting B cells as a starting material. These cells, as opposed to activated B cells, retain their surface-bound immunoglobulin, thereby rendering them amenable to antigen-specific selection.

10

Brief description of the drawings

Figure 1A and 1B illustrate data on the growth of B cells on feeder layers of irradiated L cells expressing CDw32 with and without anti-CD40 monoclonal antibody and with and without IL-4.

15

Figure 2 illustrates the growth of resting B cells in response to anti-CD40 antibody presented in different ways.

20

DETAILED DESCRIPTION OF THE INVENTION

Resting B cells for use in the invention can be obtained from a variety of sources by a variety of means, e.g. DiSabato et al. eds., Meth. in Enzymol., Vol. 108 (1984), and James et al (cited above). Preferably, B cells are obtained from peripheral blood, spleen, or tonsils. Most preferably, B cells are obtained from tonsils using the following technique: Tonsils are dissociated with wire mesh in phosphate buffered saline, pH 7.2, to obtain single cell suspensions. Mononuclear cells are separated by the standard Ficoll-Hypaque gradient method. To obtain purified B cell populations, T cells are removed from the mononuclear cells by twice rosetting with 2-aminoethylisothiuronium bromide treated sheep erythrocytes. Adherent cells (monocytes) are removed from the T cell-depleted mononuclear cells

25

30

35

- 4 -

by incubating T cell-depleted mononuclear cells (in batches of approximately  $2.5 \times 10^8$  cells) in plastic flasks containing 25 ml RPMI 1640 with 10% fetal calf serum for 1 hour at 37°C. As determined by fluorescent  
5 activated cell sorting analysis the resulting preparation contains >98% B cells, <1% T cells, and <1% monocytes. Resting B cells are obtained from this preparation by using a discontinuous gradient of Percoll (Pharmacia, Uppsala, Sweden) consisting of four  
10 solutions with densities of 1.075, 1.070, 1.060, and 1.055 g/ml. Resting B cells are recovered in the pellet, below the solution of Percoll of the highest density.

Further selection for antigen-specific subpopulation of  
15 resting B cells can be carried out by a variety of techniques including panning, rosetting, immunoadsorbent affinity chromatography, fluorescent-activated cell sorting (FACS), and the like. Casali et al, Science, Vol. 234, pgs. 476-479 (1986), describe the selection of  
20 antigen-specific B cells from peripheral blood by fluorescent-activated cell sorting. Briefly, the antigen of interest is biotinylated, incubated with the B cells, then with fluorescently labeled avidin. Cells having antibodies specific for the biotinylated antigen are  
25 sorted by the presence of the fluorescent label. Additional references describing FACS-based lymphocyte selection include Parks et al, Meth. Enzymol., Vol. 108, pgs. 197-241 (1984); and U.S. patent 4,325,706. Panning, immunoadsorbent affinity chromatography, and rosetting  
30 are described by Mage, Hubbard et al, and Haegert in Meth. Enzymol., Vol. 108, pgs. 118-124, 139-147, and 386-392, respectively (1984).

Monoclonal antibodies specific for CD40 are obtained by  
35 standard methods. Preferably, monoclonal antibodies G28-5 or Mab 89 are used as cross-linking agents. G28-5 is described by Ledbetter et al, J. Immunol., Vol. 138, pgs. 788-794 (1987) and in United Kingdom patent



- 5 -

application N° 8713650, and the hybridoma cell line producing monoclonal antibodies G28-5 is deposited at the American Type Culture Collection (ATCC) (Rockville, MD) under accession number HB 9110. Mab 89 is described in Valle et al. Eur. J. Immunol., Vol. 19, pgs. 1463-1467 (1989), and the hybridoma cell line producing monoclonal antibodies Mab 89 has been deposited on September 14, 1989 with the European Collection of Animal Cell Cultures, PHLS Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wilts. SP4 OJG, U.K. under accession number 89091401. Briefly, Mab 89 was obtained as follows. Eight week old BALB/c mice were injected i.p. four times at 3 week intervals with  $5.0 \times 10^6$  anti-IgM antibody activated tonsillar B cells. Three days after the last injection, spleen cells were collected and fused with NS1 myeloma cells (ratio 5:1) with the use of polyethylene glycol 1000 (Merck). After overnight incubation at 37°C in a 50 ml flask in complete RPMI 1640 medium containing 10% heat inactivated fetal bovine serum, 2mM glutamine, 100 IU/ml penicillin and 100 µg/ml streptomycin, the cell suspension was distributed in 24-well plates in medium supplemented with hypoxanthine and azaserine. Hybridoma supernatants were screened for their ability to bind to Jijoye cells, tonsil mononuclear cells and anti-IgM antibody activated B cells.

Several different substrates can be used to immobilize the anti-CD40 monoclonal antibodies, such as microspheres, erythrocytes, irradiated hybridomas expressing surface anti-CD40, and the like. Preferably, mammalian cell lines capable of stable expression of the FcγR are produced by co-transfecting a host mammalian cell with a vector carrying a selectable marker and a vector carrying a host-compatible promoter and a cDNA insert capable of encoding FcγRII. A cDNA clone carrying such an insert, pcD-hFcγR-16.2, is available from the ATCC under accession number 67565, and is described in

- 6 -

Stuart et al, J.Exp. Med., Vol. 166, pgs. 1668-1684 (1987). The vector is similar to the pcD shuttle vector described by Okayama and Berg, Mol. Cell. Biol., Vol. 2, pgs. 161-170 (1982), and Vol. 3, pgs. 280-289 (1983),  
5 except that the SV40 promoter has been modified to improve expression by the downstream insertion of a portion of the long terminal repeat from a HTLV(I) retrovirus, as described by Takebe et al, Mol. Cell. Biol., Vol. 8, pgs. 466-472 (1988). The vector is  
10 conveniently propagated in E. coli K12 strain MC1061, described in J. Mol. Biol., Vol. 138, pg. 179 (1980).

For pcD-hFc $\gamma$ R-16.2, hosts include Chinese hamster ovary cells and mouse L cells, such as a thymidine kinase  
15 deficient mutant (tk<sup>-</sup>) L cell available from the American Type Culture Collection under accession number CCL 1.3. The selectable marker allows one to select host cells which have a high probability of containing the Fc $\gamma$ R gene fully integrated into the host genome.  
20 Typically, the ratio of pcD-hFc $\gamma$ R-16.2 to the marker containing vector in the transfection solution is about 10:1. Thus, if the marker gene is integrated into the host genome, it is very likely that pcD-hFc $\gamma$ R-16.2 will also be integrated by virtue of its higher  
25 concentration. The selectable marker also provides a means of preventing the cultures of desired transformants from being overgrown by revertant cells. tk<sup>-</sup> mouse L cells were cotransfected with pcD-hFc $\gamma$ R-16.2 and pSV2tk, a pSV2 plasmid carrying a thymidine kinase  
30 gene under control of the SV40 early promoter. The pSV2 is described in Mulligan et al., Science, Vol. 209, pgs. 1422-1427 (1980); Subramani et al. Mol. Cell. Biol., Vol. 1, pgs. 854-864 (1981); and is available from the American Type Culture Collection under  
35 accession number 37146. Both plasmids are amplified in E. coli, e.g. strain HB101 available from the ATCC under accession number 33694, and purified by cesium chloride equilibrium centrifugation. A suspension of about 1 x

- 7 -

10<sup>5</sup> of tk<sup>-</sup> L cells in 10 ml of Dulbecco's Modified Eagle medium (DME) with 10% fetal bovine serum is placed in a Falcon 3003 dish and cultured at 37°C for 20 hours in a 5% carbon dioxide gas incubator, after which the medium is replaced by 10 ml of fresh DME with 10% fetal bovine serum. The culture is incubated for an additional 4 hours. After incubation 0.5 ml of soluble A (50 mM Hepes, 280 mM NaCl, 1.5 mM sodium phosphate buffer, pH 7.22) and 0.5 ml of solution B (2M CaCl<sub>2</sub>, 10 mg pcD-Fc $\gamma$ R-16.2, 1 mg pSV2tk) are added to the culture medium, and the culture is incubated at 37°C for 24 hours in a 5% CO<sub>2</sub> atmosphere, after which the cells are placed in a selective medium with HAT (e.g. Sigma Chemical Co., St. Louis, MO). After two weeks the surviving colonies are subcloned by limiting dilution, and clones are assayed for expression of Fc $\gamma$ R.

Preferably, IL-2, IL-4, IL-6, or INF- $\gamma$ , either alone or in combination, is added to the B cell culture at a concentration of about 1 nanomolar. Alternatively, the concentration of IL-4 may be expressed in terms of units/ml, where units are defined as in Yokota et al, Proc. Natl. Acad. Sci., Vol. 83, pgs. 5894-5898 (1986). There a unit of IL-4 is defined as the amount of IL-4 required to cause half-maximal stimulation of tritiated thymidine uptake by 5 x 10<sup>3</sup>/200  $\mu$ l T cells which were preactivated for 3 days with phytohemagglutinin and then extensively washed. Preferably, B cell cultures include about 100 U/ml of IL-4.

### EXAMPLES

#### Example 1. Longterm Culture of Human B Cells Dependent on anti-CD40 Antibody and IL-4

2x10<sup>5</sup> purified spleen B cells in 500  $\mu$ l complete culture medium were seeded in wells of 48-well microplates

- 8 -

containing  $2.5 \times 10^4$  irradiated CDw32 L cells with 1  $\mu\text{g/ml}$  anti-CD40 Mab 89 with or without 100 U/ml IL-4. Cultures incubated with either Mab 89 or Mab 89 plus IL-4 were divided at day 5 into two wells plated at  $2.5 \times 10^4$  irradiated CDw32 L cells with or without the original stimulant. Enumeration of viable B cells using Trypan Blue exclusion was carried out on a haemocytometer. Figure 1A shows the degree of B cell population growth for each culture condition. Cell numbers counted in one well at days 7, 9 and 13 have been doubled to take into account the splitting of the culture at day 5. The cell numbers have been evaluated in ten identical wells and the coefficient of variation was found to be less than 10%. Curve 1 of Fig. 1A illustrates the growth of B cells cultured on CDw32 L cells without Mab 89 and without IL-4. Curve 2 illustrates the growth of B cells cultured initially with 1  $\mu\text{g/ml}$  Mab 89, then at day 5 the culture was split and half of the cells were transferred to another well with  $2.5 \times 10^4$  irradiated CDw32 L cells with 1  $\mu\text{g/ml}$  Mab 89. Curve 3 illustrates the growth of B cells cultured initially with 1  $\mu\text{g/ml}$  Mab 89, then at day 5 the culture was split and half of the cells were transferred to another well with  $2.5 \times 10^4$  irradiated CDw32 L cells without Mab 89. Curve 4 illustrates the growth of B cells cultured initially with 1  $\mu\text{g/ml}$  Mab 89 and 100 U/ml IL-4, then at day 5 the culture was divided and half of the cells were transferred to another well with  $2.5 \times 10^4$  irradiated CDw32 L cells and 1  $\mu\text{g/ml}$  Mab 89 and 100 U/ml IL-4. Curve 5 illustrates the growth of B cells cultured initially with 1  $\mu\text{g/ml}$  Mab 89 and 100 U/ml IL-4, then at day 5 the culture was divided and half of the cells were transferred to another well with  $2.5 \times 10^4$  irradiated CDw32 L cells but without either Mab 89 or IL-4. The enhancing effect of CD40 cross linking in the presence of IL-4 is clearly seen.

In a separate experiment, purified tonsillar B cells

- 9 -

were cultured at  $10^5$  cells/ml on irradiated CDw32 L cells and 100 U/ml IL-4 in 500  $\mu$ l of complete medium in wells of 48-well microplates. Cells were enumerated at the indicated times shown on Fig. 1B and cultures were re-initiated at the end of each week by seeding  $10^5$  B cells into new wells containing freshly irradiated CDw32 L cells, and fresh medium containing 1  $\mu$ g/ml Mab 89 and 100 U/ml IL-4. Curve 1 illustrates the theoretical B cell population size if depleted culture media did not have to be replaced. Curves 2 through 5 illustrate the actual B cell populations in the initial culture and in the re-initiated cultures. Curves 6 and 7 show the decline in population size when a sample of B cell culture is re-initiated without Mab 89.

15

Example 2 Further enhancement of B cell growth by IL-6 and IFN- $\gamma$

The growth enhancing effects of various cytokines were tested.  $5 \times 10^3$  purified tonsillar B cells were cultured on  $5 \times 10^3$  irradiated CDw32 L cells with 1  $\mu$ g/ml Mab 89 in conical microwells. Tritiated thymidine uptake (after a 16 h pulse with 1  $\mu$ Ci) was assayed at the time points indicated in the table below. Each value in the table is a means of triplicate determinations. Cytokine concentrations were 25 U/ml IL-4; 2.5 IU/ml IL-1; 20 IU/ml IL-2; 50 U/ml IL-6; and 1000 IU/ml IFN- $\gamma$ . A strong synergistic growth-inducing effect is seen between IL-4 and IFN- $\gamma$  at day 8.

30

- 10 -

Table I

5	Cytokine(s) Added	Tritiated Thymidine Uptake (cpm x 10 <sup>-3</sup> )			
		Day 2	Day 4	Day 6	Day 8
10	--	1.5	5.3	7.0	5.1
	IL-4	3.1	7.9	13.3	21.8
	IL-2	2.3	4.4	12.7	n.d.
	IL-6	1.1	9.3	25.0	13.0
	IFN- $\gamma$	4.6	6.7	16.6	14.0
	IL-4 + IL-2	1.8	13.2	18.6	18.4
	IL-4 + IL-6	1.9	17.8	22.8	32.0
	IL-4 + IFN- $\gamma$	4.9	21.5	34.1	60.9

20 Example 3. Antibody production by B cells stimulated  
with Mab 89 presented on CDw32-transfected L  
cells

25 2.5x10<sup>5</sup> purified B cells were cultured with or without  
2.5x10<sup>4</sup> irradiated CDw32 L cells, with or without 0.5  
 $\mu$ g/ml Mab 89, and with or without 100 U/ml IL-4.  
Supernatants were harvested at day 8 and immunoglobulin  
concentrations were determined by ELISA. The results for  
the various isotypes are shown in Table II.

- 11 -

Table II

5	Culture Conditions	Concentration (ng/ml)			
		IgG	IgA	IgM	IgE
	Control	80	20	125	<0.2
10	Mab 89	225	70	380	- -
	IL-4	100	<10	80	<0.2
	Mab 89 + IL-4	105	30	170	<0.2
	L cells	210	10	290	<0.2
	L cells + IL-4	650	200	490	<0.2
15	L cells + Mab 89	1800	40	320	<0.2
	L cells + Mab 89 + IL-4	5825	650	31200	458

20 Example 4. Stimulation of B cell growth by irradiated  
hybridoma 89 cells

25 The growth-inducing effect of a hybridoma expressing  
surface anti-CD40 antibody was tested. Six experimental  
conditions were examined; and columns 1 to 6 of Figure 2  
correspond to the conditions listed as follows: a  
control consisting of microtiter plate wells seeded with  
 $10^5$  purified B cells (column 1); a control consisting of  
microtiter plate wells seeded with  $10^5$  purified B cells  
30 and 1  $\mu$ g/ml Mab 89 (column 2); a control consisting of  
microtiter plate wells seeded with  $10^4$  irradiated  
hybridoma 89.1.4 cells (this is a derivative of  
hybridoma 89 which expresses antibody on its surface)  
(column 3); a control consisting of microtiter plate  
wells seeded with  $10^5$  purified B cells and  $10^4$  cells of  
35 an irradiated and unrelated hybridoma (column 4); a  
control consisting of microtiter plate wells seeded with

- 12 -

10<sup>5</sup> purified B cells and 10<sup>4</sup> irradiated hybridoma 89.1.4 cells (column 5); and a control consisting of microtiter plate wells seeded with 10<sup>5</sup> purified B cells and 10<sup>4</sup> irradiated CDw32 transfected L cells and 1 µg/ml of Mab 89 (column 6). Cell growth under the respective conditions was assayed by tritiated thymidine incorporation. The results are shown in Figure 2. The immobilized anti-CD40 on irradiated hybridoma 89.1.4 is nearly as effective as that on CDw32 transfected L cells in inducing growth in resting B cells.

Example 5. Enhancement of EBV infection of B cells by Mab 89

15 An important way to establish antibody-producing human B cell lines is by infecting the B cells with Epstein Barr virus (EBV), e.g. James, Scand. J. Immunol., Vol. 29, pg. 257 (1989). However, the infection procedure is very inefficient, e.g. Stein et al. Cell. Immunol., Vol. 79, 20 pg. 309 (1983). It was discovered that the presence of a CD40 cross-linking agent increases the efficiency of B cell infection. Infection efficiency was measured as a function of initial B cell numbers and the presence or absence of Mab 89, IL-4, or IL-6. Cultures were 25 performed in 48-well (flat bottoms) plates for 10<sup>5</sup>-cell cultures (each also containing 2.5x10<sup>4</sup> irradiated CDw32 L cells) and in 96-well (round bottoms) plate for 100-cell and single cell colonies (each also containing 5.10<sup>3</sup> irradiated CDw32 L cells). Factor concentrations 30 were as follows: 1 µg/ml of Mab 89, 100 U/ml of IL-4, and 50 U/ml of IL-6. Table III lists the fraction of wells from which continuous EBV-transformed B cell lines were obtained for the various starting conditions and culture conditions.



Table III

Culture Conditions				Initial Cell Number	
(Item added):				(wells with transformants/total number of wells)	
L cells	Mab 89	IL-4	IL-6	10 <sup>5</sup>	1
-	-	-	-	0/48	0/288
+	-	-	-	48/48	1/288
+	+	-	-	48/48	8/288
+	+	+	-	48/48	0/288
+	+	-	+	48/48	4/288
+	+	+	+	48/48	2/288

- 14 -

Besides enhanced EBV infection, the Mab 89/L cell system also affects antibody production by the EBV infected B cells.  $10^5$  resting B cells were cultured on  $2.5 \times 10^4$  irradiated L cells expressing CDw32 and 1  $\mu\text{g/ml}$  Mab 89 and EBV. Cells were enumerated at day 8 and immunoglobulin levels were measured by ELISA. Table IV lists the results and shows that the cells produce very high levels of IgE under these conditions.

10 Table IV

15	Culture conditions	Cell Number $\times 10^5$	Concentration (ng/ml)			
			IgG	IgA	IgM	IgE
20	L cells + EBV	0.45	667	105	959	<0.2
	L cells + Mab 89	3.7	1245	639	1717	<0.2
	+ EBV					
	L cells + Mab 89	6	683	87	572	478
	+ EBV +IL-4					

25

Example 6. Establishment of Human B Cell Clone Producing Rh Factor-Specific Monoclonal Antibodies

30 An important clinical use of anti-Rh antibodies is their injection into Rh-negative women shortly after the delivery of an Rh-positive infant to prevent the development of indigenous anti-Rh antibodies by the women which could be harmful to infants of subsequent pregnancies, e.g. Crookston, pgs. 601-608, in Rose et

35

- 15 -

al, eds., Manual of Clinical Laboratory Immunology, 3rd Ed. (American Society for Microbiology, Washington, D.C., 1986). Besides the cost and difficulty of obtaining suitable donors for the anti-Rh immunoglobulin, a frequent danger associated with such injections is the transmission of blood-borne diseases such hepatitis, AIDS, and the like. In view of this problem, an in vitro source of anti-Rh antibodies would be highly desirable.

10

Resting B lymphocytes are isolated from an Rh-negative donor having serum containing anti-Rh antibody. A subpopulation of resting B cells carrying anti-Rh surface immunoglobulin may be isolated by repeated panning of the isolated B lymphocytes by the technique described by Mage (cited above), modified in the following manner: Instead of using a tissue culture dish coated with antibody specific for the anti-Rh antibody, the tissue culture dish is coated with anti-biotin antibody, and prior to addition to the tissue culture dish the isolated B lymphocytes are incubated with biotinylated Rh antigen. Cells binding the biotinylated Rh antigen are then isolated by panning as described by Mage (cited above). Alternatively, the resting B lymphocytes are isolated by fluorescent-activated cell sorting (FACS) using fluorescently labeled Rh antigen, or by rosetting following standard procedures, e.g. Elliott et al, Meth. Enzymol., Vol. 108, pgs 49-64 (1984).

30

The isolated anti-Rh resting B cells are then distributed among the wells (about  $10^5$  B cells per well) of a microtiter plate, each well having previously been seeded with about  $10^4$  CDw32-transfected, irradiated L cells, and each well containing 0.4 ml of medium (RPMI 1640 with 10% fetal calf serum, and 2 mM glutamine)

35

- 16 -

further containing 0.5 mg/ml of Mab 89 and 100 U/ml of IL-4. Cultures are expanded into larger containers and harvested for anti-Rh antibody after several weeks.

- 17 -

## CLAIMS:

1. A method for making human B cell lines, the method comprising the steps of:
  - 5 isolating a human resting B cell having CD40 antigens and having immunoglobulin of a desired specificity; and
  - culturing the human resting B cell in the presence of an agent capable of cross-linking CD40 antigens.
- 10 2. The method of claim 1 wherein said cross-linking agent is an immobilized monoclonal antibody specific for said CD40 antigen.
- 15 3. The method of claim 2 wherein the step of culturing further includes culturing in the presence of interleukin-4 and/or interferon- $\gamma$ .
- 20 4. The method of claim 3 wherein said immobilized monoclonal antibody is attached to Fc $\gamma$ RII receptors expressed by non-replicating mammalian cells.
- 25 5. The method of claim 4 wherein said monoclonal antibody is selected from the group consisting of Mab 89 and G28-5 and wherein said non-replicating mammalian cells are mouse L cells stably transformed by pcD-hFc $\gamma$ R-16.2.
- 30 6. A method of producing Epstein-Barr virus-transformed human B cells, the method comprising the step of culturing human B cells in the presence of Epstein-Barr virus and an agent capable of cross-linking CD40 antigens.
- 35 7. The method of claim 6 wherein said agent is an

- 18 -

immobilized monoclonal antibody specific for said CD40 antigen.

5 8. The method of claim 7 wherein said immobilized monoclonal antibody is attached to Fc $\gamma$ RII receptors expressed by non-replicating mammalian cells.

10 9. The method of claim 8 wherein said monoclonal antibody is selected from the group consisting of Mab 89 and G28-5 and wherein said non-replicating mammalian cells are mouse L cells stably transformed by pcD-hFc $\gamma$ R-16.2.

International Application No: PCT/

/

**MICROORGANISMS**Optional Sheet in connection with the microorganism referred to on page 5, lines 7-11 of the description <sup>1</sup>**A. IDENTIFICATION OF DEPOSIT :**Further deposits are identified on an additional sheet ☐ <sup>2</sup>Name of depositary institution <sup>4</sup>

EUROPEAN COLLECTION OF ANIMAL CELL CULTURES

Address of depositary institution (including postal code and country) <sup>4</sup>PHLS Centre for Applied Microbiology & Research  
PORTON DOWN, Salisbury ; Wilts. SP4 0JG UK.Date of deposit <sup>3</sup>

14TH SEPTEMBER. 1989

Accession Number <sup>4</sup>

89 091401

**B. ADDITIONAL INDICATIONS** <sup>7</sup> (leave blank if not applicable). This information is continued on a separate attached sheet ☐**C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** <sup>8</sup> (If the indications are not for all designated States)

In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). The restriction must be also applied

- in Norway according to Articles 22 and 33.3 of the Norway Patent Act
- in Finland according to article 22.7 of Finland Patent Law of December 15, 1967 modified by the Law of May 10, 1985.

**D. SEPARATE FURNISHING OF INDICATIONS** <sup>9</sup> (leave blank if not applicable)The indications listed below will be submitted to the International Bureau later <sup>9</sup> (Specify the general nature of the indications e.g., "Accession Number of Deposit")**E.** ☒ This sheet was received with the International Application when filed (to be checked by the receiving Office)

(Authorized Officer)

Stefanzki

☐ The date of receipt (from the applicant) by the International Bureau <sup>10</sup>

-was

(Authorized Officer)

1/2




Fig. 1A




Fig. 1B



2/2







Fig. 2

# INTERNATIONAL SEARCH REPORT

International Application No **PCT/EP 90/02195**

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>5</sup> : <b>C 12 N 5/08</b>														
<b>II. FIELDS SEARCHED</b> <div style="text-align: right; font-size: small;">Minimum Documentation Searched †</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">IPC<sup>5</sup></td> <td style="border: 1px solid black; padding: 5px;">C 12 N</td> </tr> </table> <div style="text-align: center; font-size: x-small; margin-top: 5px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *</div>			Classification System	Classification Symbols	IPC <sup>5</sup>	C 12 N								
Classification System	Classification Symbols													
IPC <sup>5</sup>	C 12 N													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT *</b> <table border="1" style="width: 100%; border-collapse: collapse; font-size: x-small;"> <thead> <tr> <th style="width: 10%;">Category *</th> <th style="width: 70%;">Citation of Document, †† with indication, where appropriate, of the relevant passages ‡</th> <th style="width: 20%;">Relevant to Claim No. ‡</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td style="vertical-align: top;"> <b>Biological Abstracts, vol. 88, 1989, .</b>  <b>A. Valle et al.: "Activation of human B lymphocytes through CD40 and interleukin 4",</b>  <b>see page AB-554, abstract 108680</b>  <b>&amp; Eur. J. Immunol. 19(8): 1463-1468. 1989</b>  <div style="text-align: center;">--</div> </td> <td style="text-align: center; vertical-align: top;">1-9</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td style="vertical-align: top;"> <b>Biological Abstracts, vol. 36, 1989,</b>  <b>A Valle et al.: "Activation of human B cells with a new monoclonal antibody MAB 89 specific for the CD-W-40 antigen",</b>  <b>see abstract 114250</b>  <div style="text-align: center;">--</div> </td> <td style="text-align: center; vertical-align: top;">1-9</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">Y</td> <td style="vertical-align: top;"> <b>Biological Abstracts, vol. 87, no. 12, 1989, (Philadelphia, PA, US),</b>  <b>J.L. Lasky et al.: "Characterization and growth factor requirements of SJL lymphomas: II. Interleukin 4 dependence</b>  <div style="text-align: right;">./.</div> </td> <td style="text-align: center; vertical-align: top;">1</td> </tr> </tbody> </table>			Category *	Citation of Document, †† with indication, where appropriate, of the relevant passages ‡	Relevant to Claim No. ‡	X	<b>Biological Abstracts, vol. 88, 1989, .</b> <b>A. Valle et al.: "Activation of human B lymphocytes through CD40 and interleukin 4",</b> <b>see page AB-554, abstract 108680</b> <b>&amp; Eur. J. Immunol. 19(8): 1463-1468. 1989</b> <div style="text-align: center;">--</div>	1-9	X	<b>Biological Abstracts, vol. 36, 1989,</b> <b>A Valle et al.: "Activation of human B cells with a new monoclonal antibody MAB 89 specific for the CD-W-40 antigen",</b> <b>see abstract 114250</b> <div style="text-align: center;">--</div>	1-9	Y	<b>Biological Abstracts, vol. 87, no. 12, 1989, (Philadelphia, PA, US),</b> <b>J.L. Lasky et al.: "Characterization and growth factor requirements of SJL lymphomas: II. Interleukin 4 dependence</b> <div style="text-align: right;">./.</div>	1
Category *	Citation of Document, †† with indication, where appropriate, of the relevant passages ‡	Relevant to Claim No. ‡												
X	<b>Biological Abstracts, vol. 88, 1989, .</b> <b>A. Valle et al.: "Activation of human B lymphocytes through CD40 and interleukin 4",</b> <b>see page AB-554, abstract 108680</b> <b>&amp; Eur. J. Immunol. 19(8): 1463-1468. 1989</b> <div style="text-align: center;">--</div>	1-9												
X	<b>Biological Abstracts, vol. 36, 1989,</b> <b>A Valle et al.: "Activation of human B cells with a new monoclonal antibody MAB 89 specific for the CD-W-40 antigen",</b> <b>see abstract 114250</b> <div style="text-align: center;">--</div>	1-9												
Y	<b>Biological Abstracts, vol. 87, no. 12, 1989, (Philadelphia, PA, US),</b> <b>J.L. Lasky et al.: "Characterization and growth factor requirements of SJL lymphomas: II. Interleukin 4 dependence</b> <div style="text-align: right;">./.</div>	1												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ††</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 50%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"Z" document member of the same patent family</p> </div> </div>														
<b>IV. CERTIFICATION</b> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;">           Date of the Actual Completion of the International Search  <div style="text-align: center; font-weight: bold;">6th March 1991</div> </td> <td style="width: 50%; border: none; vertical-align: top;">           Date of Mailing of this International Search Report  <div style="text-align: center; font-weight: bold;">16.04.91</div> </td> </tr> <tr> <td style="width: 50%; border: none; vertical-align: top;">           International Searching Authority  <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div> </td> <td style="width: 50%; border: none; vertical-align: top;">           Signature of Authorized Officer  <div style="text-align: center;">   <b>Alfred Prein</b> </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">6th March 1991</div>	Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold;">16.04.91</div>	International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">   <b>Alfred Prein</b> </div>								
Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">6th March 1991</div>	Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold;">16.04.91</div>													
International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">   <b>Alfred Prein</b> </div>													

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, " with indication, where appropriate, of the relevant passages	Relevant to Claim No.
	<p>of the in vitro cell line, CRCS-X, and influence of other cytokines", see pages AB-646-647, abstract 127968, &amp; Eur. J. Immunol. 19(2): 365-372. 1989</p> <p>--</p>	
Y	<p>Biological Abstracts, vol. 79, no. 11, 1985, (Philadelphia, PA, US), R. Frade et al.: "Enhancement of human B cell proliferation by an antibody to the complement C3d receptor, the glycoprotein gp1 40 molecule", see page AB-451, abstract 95695, &amp; Eur. J. Immunol. 15(1): 73-76. 1985</p> <p>--</p>	1
Y	<p>The Journal of Immunology, vol. 142, no. 5, 1 March 1989, The American Association of Immunologists, (US), J.B. Splawski et al.: "Immunomodulatory role of Ig by human B cells", pages 1569-1575 see the whole article</p> <p>-----</p>	1

(17920) X/A 18 3349 214

**THIS PAGE BLANK (USPTO)**